Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gareth T Jones

Showing results (121-130 of 147) with videos related to

Pageof 15
Sort By:
Annals of the Rheumatic Diseases|January 29, 2013
The characterisation and determinants of quality of life in ANCA associated vasculitisNeil Basu, Andrew McClean, Lorraine Harper, et al.
Rheumatology (Oxford, England)|June 7, 2013
Explaining fatigue in ANCA-associated vasculitisNeil Basu, Andrew McClean, Lorraine Harper, et al.
Rheumatology (Oxford, England)|February 4, 2014
Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitisNeil Basu, Andrew McClean, Lorraine Harper, et al.
Rheumatology Advances in Practice|May 17, 2023
Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scopeSizheng Steven Zhao, Stephanie R Harrison, Antoni Chan, et al.
The Journal of Rheumatology|April 15, 2024
Cut-Offs for Disease Activity States in Axial Spondyloarthritis With Ankylosing Spondylitis Disease Activity Score (ASDAS) Based on C-Reactive Protein and ASDAS Based on Erythrocyte Sedimentation Rate: Are They Interchangeable?Stylianos Georgiadis, Lykke Midtbøll Ørnbjerg, Brigitte Michelsen, et al.
Rheumatology (Oxford, England)|April 8, 2025
Executive Summary: The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDsSizheng Steven Zhao, Stephanie R Harrison, Ben Thompson, et al.
Rheumatology (Oxford, England)|April 8, 2025
The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDsSizheng Steven Zhao, Stephanie R Harrison, Ben Thompson, et al.
BMC Rheumatology|July 11, 2025
The relationship between lifestyle factors and outcome of treatment with TNFα inhibitors in axial spondyloarthritis - results from 14 European countriesGareth T Jones, Ovidiu Rotariu, Ross MacDonald, et al.
BMC Rheumatology|July 2, 2025
Interchangeability of patient pain, fatigue and global scores in patients with spondyloarthritis - a registry-based simulation studyStylianos Georgiadis, Daniela Di Giuseppe, Almut Scherer, et al.
BMC Medical Research Methodology|February 28, 2025
Handling of missing component information for common composite score outcomes used in axial spondyloarthritis research when complete-case analysis is unbiasedChristos Polysopoulos, Stylianos Georgiadis, Lykke Midtbøll Ørnbjerg, et al.
Pageof 15

Showing results (121-130 of 147) with videos related to

Sort By:
Pageof 15
Annals of the Rheumatic Diseases|January 29, 2013
The characterisation and determinants of quality of life in ANCA associated vasculitisNeil Basu, Andrew McClean, Lorraine Harper, et al.
Rheumatology (Oxford, England)|June 7, 2013
Explaining fatigue in ANCA-associated vasculitisNeil Basu, Andrew McClean, Lorraine Harper, et al.
Rheumatology (Oxford, England)|February 4, 2014
Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitisNeil Basu, Andrew McClean, Lorraine Harper, et al.
Rheumatology Advances in Practice|May 17, 2023
Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scopeSizheng Steven Zhao, Stephanie R Harrison, Antoni Chan, et al.
The Journal of Rheumatology|April 15, 2024
Cut-Offs for Disease Activity States in Axial Spondyloarthritis With Ankylosing Spondylitis Disease Activity Score (ASDAS) Based on C-Reactive Protein and ASDAS Based on Erythrocyte Sedimentation Rate: Are They Interchangeable?Stylianos Georgiadis, Lykke Midtbøll Ørnbjerg, Brigitte Michelsen, et al.
Rheumatology (Oxford, England)|April 8, 2025
Executive Summary: The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDsSizheng Steven Zhao, Stephanie R Harrison, Ben Thompson, et al.
Rheumatology (Oxford, England)|April 8, 2025
The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDsSizheng Steven Zhao, Stephanie R Harrison, Ben Thompson, et al.
BMC Rheumatology|July 11, 2025
The relationship between lifestyle factors and outcome of treatment with TNFα inhibitors in axial spondyloarthritis - results from 14 European countriesGareth T Jones, Ovidiu Rotariu, Ross MacDonald, et al.
BMC Rheumatology|July 2, 2025
Interchangeability of patient pain, fatigue and global scores in patients with spondyloarthritis - a registry-based simulation studyStylianos Georgiadis, Daniela Di Giuseppe, Almut Scherer, et al.
BMC Medical Research Methodology|February 28, 2025
Handling of missing component information for common composite score outcomes used in axial spondyloarthritis research when complete-case analysis is unbiasedChristos Polysopoulos, Stylianos Georgiadis, Lykke Midtbøll Ørnbjerg, et al.
Pageof 15